Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2026 05:00 ET | Source: HepaRegeniX

HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026

Tuebingen, Germany, May 13, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its...